Phase 2 Plasma Clinical Trials
43 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 43 trials
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 1Phase 2
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Multiple MyelomaPlasmacytoma
Shenzhen Geno-Immune Medical Institute20 enrolled2 locationsNCT06429150
Recruiting
Phase 2
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Smoldering Plasma Cell Myeloma
Emory University68 enrolled1 locationNCT04776395
Recruiting
Phase 2
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Multiple MyelomaPlasma Cell NeoplasmMalignant Plasma Cell Neoplasm
M.D. Anderson Cancer Center30 enrolled1 locationNCT05336383
Recruiting
Phase 2
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center40 enrolled1 locationNCT04216524
Recruiting
Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled125 locationsNCT04840602
Recruiting
Phase 2
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
AbbVie14 enrolled7 locationsNCT07387471
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia (PCL)
The First Hospital of Jilin University25 enrolled1 locationNCT07509086
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled28 locationsNCT04643002
Recruiting
Phase 2
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Multiple MyelomaPlasma Cell Leukemia
University of Utah120 enrolled1 locationNCT05405387
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+4 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905
Recruiting
Phase 2
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT05870917
Recruiting
Phase 2
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 2
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Plasma Cell Myeloma Refractory
Sanofi64 enrolled34 locationsNCT06356571
Recruiting
Phase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+7 more
Fred Hutchinson Cancer Center54 enrolled1 locationNCT06013423
Recruiting
Phase 2
Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETS28 enrolled18 locationsNCT04915248
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Lymphoplasmacytic LymphomaWaldenström MacroglobulinemiaB-Cell Lymphoproliferative Disorder+1 more
Shayna Sarosiek, MD30 enrolled1 locationNCT06986174
Recruiting
Phase 2
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Multiple MyelomaPlasma Cell Leukemia
University of Utah40 enrolled1 locationNCT06517017
Recruiting
Phase 2
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
Memorial Sloan Kettering Cancer Center40 enrolled8 locationsNCT07231952